Virpax Pharmaceuticals Inc. - VRPX Total Company Value-to-Revenue Ratio

Public company logo of Virpax Pharmaceuticals (VRPX)

Innovative non-opioid analgesic delivery methods are creating a key growth driver for Virpax Pharmaceuticals. The change in the enterprise value-to-revenue multiple visualizes this trend, where shows the level of this metric. Prospects are supported by hospital demand for safe therapy and the management's scientific foundation, although the company's financial stability depends on the periodic raising of external capital.

Virpax Pharmaceuticals - VRPX Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

Financial and market metric breakdowns for Virpax Pharmaceuticals Inc. (VRPX)

- share price and expert price forecast:
- money and cash flow information:
Fundamental valuation:Virpax VRPX
Mass-produced product of Virpax Pharmaceuticals, Inc.

To filter investment risks, it is essential to understand how the market values a business relative to its operating income. This indicator is calculated as the ratio of enterprise value (EV) to revenue; however, the revenue-based valuation of Virpax Pharmaceuticals (VRPX) remains speculative due to the absence of current sales during the clinical development stage.